Tecartus (brexucabtagene autoleucel)

pCPA File Number: 21582

Negotiation Status:

Concluded with an LOI

Indication(s):

Mantle cell lymphoma (MCL), relapsed or refractory, in adult patients who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)

Sponsor/Manufacturer:

Gilead Sciences Canada Inc.

CDA-AMC Project Number:

PG0219-000

pCPA Engagement Letter Issued:

2021-11-22

Negotiation Process Concluded:

2022-11-10